Try our Advanced Search for more refined results

Karth v. Keryx Biopharmaceuticals, Inc et al

Track this case

Case Number:

1:16-cv-11745

Court:

Massachusetts

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

Denise J. Casper

Firms

Companies

Sectors & Industries:

  1. September 23, 2019

    Disclosures Let Keryx Escape Kidney Drug Stock Suit

    A Massachusetts federal judge handed Keryx Biopharmaceuticals Inc. a win in a proposed shareholder class action on Monday, ruling that the sole remaining plaintiff bought his shares of the company after vital information about its kidney drug had already been disclosed.

  2. June 19, 2019

    Keryx Fights Investor's Bid To Lead Kidney Drug Stock Suit

    A Keryx investor seeking to lead a shareholder class action over a 2016 stock drop shouldn't head up the suit because his shares were bought through a now-defunct trust and the vital information allegedly hid by the company was actually disclosed, a Massachusetts federal judge heard Wednesday.

  3. April 30, 2019

    Keryx Investors Seek Class Cert. In Kidney Drug Stock Case

    A Keryx Biopharmaceuticals Inc. investor on Tuesday urged a Massachusetts federal judge to certify a class of shareholders he claims lost money after the company allegedly concealed potential problems with manufacturing its kidney disease-fighting drug Auryxia.

  4. March 14, 2019

    Investors Fight Keryx Bid To Ditch Kidney Drug Stock Case

    Shareholders of Keryx Biopharmaceuticals Inc. told a Massachusetts federal judge Wednesday that the drug company's latest attempt to ditch claims it hid potential snags in the manufacturing of its drug Auryxia from shareholders is a rehash of old arguments already rejected by the court.

  5. February 28, 2019

    Keryx Says It Didn't Mislead Investors On Drug's Production

    Keryx Biopharmaceuticals Inc. asked a Massachusetts federal judge Wednesday to toss the sole remaining claim in an otherwise dismissed shareholders securities fraud suit, saying the stockholders' misunderstanding — not Keryx's alleged deceptive wording — misled them about the production of the kidney disease drug Auryxia.

  6. August 16, 2018

    Keryx Shouldn't Get 2nd Chance To Ax Stock Suit, Court Told

    Investors in Keryx Biopharmaceuticals Inc. shot back Thursday at the company's attempt to reargue its motion to dismiss a proposed class action alleging the company misled investors to believe it had mitigated supply chain risks before its stock tumbled due to a production delay.

  7. August 03, 2018

    Keryx Wants Auryxia Stock-Drop Suit Reconsidered

    Keryx Biopharmaceuticals Inc. has refused to accept a judge's decision that a proposed class action validly alleged that the company misled investors to believe it had mitigated supply chain risks before its stock tumbled due to a production delay of Auryxia, a treatment for symptoms of renal disease.

  8. July 20, 2018

    Keryx Trims, But Can't Scrap Shareholder Stock-Drop Suit

    Keryx Biopharmaceuticals Inc.'s bid to escape a proposed shareholder class action claiming it inflated its stock price by hiding a drug's supply chain problems was rejected by a Massachusetts federal judge, who however agreed to trim an allegation based on the company's statements about its financial prospects.

  9. October 03, 2017

    Keryx Seeks To Scrap Shareholder Stock-Drop Suit

    Keryx Biopharmaceuticals Inc. argued Monday that it shouldn't have to face a shareholder class action over alleged problems with a drug supply chain that resulted in a decline in stock value, claiming in a Massachusetts federal court filing that the shareholders failed to recognize the need for a different contractor for each production phase. 

  10. August 29, 2016

    Pharma Co.'s Supply Chain Lies Caused Stock Drop, Suit Says

    Keryx Biopharmaceuticals Inc. hid major problems with the supply chain for a new kidney disease treatment, leading to a 36 percent stock drop after production was delayed, shareholders alleged Friday in Massachusetts federal court.